Chryssikopoulos A, Phocas I, Rizos D, Kontoravdis A
2nd Department of Obstetrics and Gynecology, Medical School, University of Athens, Areteion Hospital, Greece.
Gynecol Endocrinol. 1997 Apr;11(2):119-26. doi: 10.3109/09513599709152522.
Twenty-one women presenting with different diseases, with absolute or relative contraindications to hormonal contraception or the use of intrauterine devices, received 300-600 micrograms/day buserelin intranasally from the 1st to the 21st day, and 5 mg/day norethisterone acetate orally from the 16th to the 23rd day of the cycle for a total of 245 cycles. Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol and testosterone were determined on days 3-5 and 13-15 of the cycle, while progesterone determinations and ovarian sonography were performed during the second half of the cycle. According to progesterone values, 92.7% of the treatment cycles were anovulatory, while in one cycle pregnancy was detected (0.4%). Values of serum LH, FSH and estradiol were low, and in most of the cycles ovarian follicular development was limited to follicles < or = 11 mm. In 21 treatment cycles (9%), statistically significant increases in FSH (p < 0.0001) and LH (p < 0.02), as well as ovarian proliferation to preovulatory follicles or luteinized follicles, were found. It appears that in spite of the high cost of medication and monitoring of patients, this regimen could be useful as an alternative in cases where other forms of contraception are contraindicated or have failed.
21名患有不同疾病、存在激素避孕或使用宫内节育器的绝对或相对禁忌证的女性，在周期的第1天至第21天每天经鼻给予300 - 600微克布舍瑞林，在周期的第16天至第23天每天口服5毫克醋酸炔诺酮，共进行了245个周期。在周期的第3 - 5天和第13 - 15天测定血清促黄体生成素（LH）、促卵泡生成素（FSH）、雌二醇和睾酮，而在周期的后半期进行孕酮测定和卵巢超声检查。根据孕酮值，92.7%的治疗周期无排卵，而在一个周期中检测到妊娠（0.4%）。血清LH、FSH和雌二醇值较低，在大多数周期中卵巢卵泡发育仅限于直径小于或等于11毫米的卵泡。在21个治疗周期（9%）中，发现FSH（p < 0.0001）和LH（p < 0.02）有统计学意义的升高，以及卵巢增殖为排卵前卵泡或黄素化卵泡。尽管药物治疗和患者监测成本高昂，但在其他避孕方式禁忌或失败的情况下，这种方案可能是一种有用的替代方法。
